Gamida rises on FDA approval for blood cancer therapy

Gamida Cell

17/04/2023 18:38

** U.S.-listed shares of Israeli cancer therapy developer
Gamida Cell Ltd GMDA.O up 30% at $1.04
    ** The U.S. Food and Drug Administration (FDA) approves
Gamida's blood cancer therapy, Omisirge
    ** FDA says it approved Omisirge to quicken recovery of
neutrophils (a subset of white blood cells) in the body and
reduce the risk of infection
    ** FDA says product is intended for use in patients 12 years
and older
    ** GMDA down about 17% YTD

 (Reporting by Vaibhav  Sadhamta)
 ((Vaibhav.Sadhamta@thomsonreuters.com;))